// App-Quantinova.ai

LBA1 : OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER2-negative early breast cancer.

Researchers

Presenter

  • Andrew Tutt

Principal Investigators

  • Bella Kaufman

  • Giuseppe Viale

  • Debora Fumagalli

  • Priya Rastogi

  • Richard D. Gelber

  • Evandro de Azambuja

  • Anitra Fielding

  • Judith Balmana Gelpi

  • Karen A. Gelmon

  • Nigel Baker

  • Amal Arahmani

  • Elzbieta Senkus-Konefka

  • Eleanor Mc Fadden

  • Vassiliki Karantza

  • Sunil R. Lakhani

  • Greg Yothers

  • Christine Campbell

  • Charles E. Geyer

Medical Centers

  • Breast Cancer Now, Toby Robins Research Centre, The Institute of Cancer Research, and The Breast Cancer Now Unit, Guy’s Hospital Cancer Centre, King's College London, London, United Kingdom

  • Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA

  • Breast Oncology Institute, Sheba Medical Center, Tel Aviv University, Tel Hashomer, Israel

  • University of Milan, Milan, Italy

  • Breast International Group, Brussels, Belgium

  • University of Pittsburgh, Pittsburgh, PA

  • Dana-Farber Cancer Institute, Harvard Medical School, Harvard TH Chan School of Public Health, and Frontier Science and Technology Research Foundation, Boston, MA

  • Institut Jules Bordet, Universite libre de Bruxelles, Brussels, Belgium

  • AstraZeneca, Gaithersburg, MD

  • Hospital Vall d Hebron, Vall d Hebron Institute of Oncology (VHIO), Barcelona, Spain

  • Department of Medical Oncology,BC Cancer,Vancouver,C

  • Canada.

  • Medical University of Gdansk, Oncology and Radiotherapy, Gdansk, Poland

  • Frontier Science (Scotland) Ltd, Kincraig, United Kingdom

  • Merck & Co., Inc., Kenilworth, NJ

  • The University of Queensland Centre for Clinical Research & Pathology Queensland, Brisbane, Australia

  • University of Pittsburgh Department of Biostatistics, and NRG Oncology Statistics and Data Management Center, Pittsburgh, PA

  • Frontier Science (Scotland) Ltd, Kincraig, United Kingdom

  • Houston Methodist Cancer Center, Houston, TX

Locations

  • United Kingdom

  • United States

  • Israel

  • Italy

  • Belgium

  • Spain

  • Canada

  • Poland

  • Australia

Companies

  • Frontier Science (Sc

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

  • Oncology (ONC)

Disease

  • Alpha-thalassemia myelodysplasia syndrome

  • Acute myelocytic leukemia

  • Breast cancer

  • Pulmonary alveolar proteinosis

  • Solid malignancies

  • Triple-negative breast cancer

Biomarkers

  • Breast cancer type 1 susceptibility protein

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • Olaparib

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Superiority

  • Multicenteric

  • Controlled

Phase

  • III

Study Id's

  • NCT02032823

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved